- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00063635
Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC) (TONIC)
27. august 2012 opdateret af: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Clinical Research Network in Nonalcoholic Steatohepatitis: Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)
The purpose of this study is to determine if therapeutic modification of insulin resistance or oxidative stress leads to improvement in serum or histologic indicators of liver injury or quality of life.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
173
Fase
- Fase 3
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
California
-
San Diego, California, Forenede Stater, 92103
- University of California, San Diego
-
San Francisco, California, Forenede Stater, 94143
- University of California, San Francisco
-
-
District of Columbia
-
Washington, District of Columbia, Forenede Stater, 20010
- Children's National Medical Center
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46202
- Indiana University
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21205
- Johns Hopkins University
-
-
Missouri
-
St. Louis, Missouri, Forenede Stater, 63110
- St. Louis University
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44109
- Case Western Reserve University
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- Texas Children's Hospital
-
-
Virginia
-
Richmond, Virginia, Forenede Stater, 23298
- Virginia Commonwealth University
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98195
- University of Washington
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
8 år til 17 år (Barn)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
- Age 8-17 years at first screening visit
- Histologic evidence of Nonalcoholic Fatty Liver Disease (NAFLD) - biopsy cannot be older than 6 months as of randomization
- ALT level >60 U/L at time of screening and on one previous occasion determined at least one month but no greater than 6 months prior to screening ALT
- Consent
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Placebo komparator: 3
Matching placebo
|
Twice daily
|
|
Aktiv komparator: 1
Metformin, 500 mg, twice daily
|
500 mg, twice daily
|
|
Aktiv komparator: 2
Vitamin E, 400 IU, twice daily
|
400 IU, twice daily
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants With Sustained Reduction in Alanine Aminotransferase (ALT) to Either 50% of Baseline Value or < 40 IU/L
Tidsramme: baseline and 96 weeks
|
The primary outcome was sustained reduction in ALT level, defined as 50% or less of the baseline level or 40 IU/L or less at each visit from 48 to 96 weeks of treatment.
|
baseline and 96 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Serum Aspartate Aminotransferase (AST)
Tidsramme: baseline and 96 weeks
|
baseline and 96 weeks
|
|
|
Change in Nonalcoholic Fatty Liver Disease (NAFLD) Score (Histologic Feature Scores Determined by Standardized Scoring of Liver Biopsies) From Baseline at 96 Weeks of Treatment
Tidsramme: baseline and 96 weeks
|
Histological activity was assessed using the NAFLD activity score on a scale of 0 to 8, with higher scores indicating more severe disease; the components of this measure include steatosis (0-3), lobular inflammation (0-3), and hepatocellular ballooning (0-2).
|
baseline and 96 weeks
|
|
Number of Participants With Improvement in Liver Fibrosis Score
Tidsramme: baseline and 96 weeks
|
Fibrosis is assessed on a scale of 0 to 4 with higher scores indicating more severe fibrosis.
This secondary outcome measure is the number of participants that experienced a decrease in fibrosis score at 96 weeks compared to baseline, which indicates improvement in fibrosis.
|
baseline and 96 weeks
|
|
Number of Participants With Improvement in Steatosis Score
Tidsramme: baseline and 96 weeks
|
Steatosis is assessed on a scale of 0 to 3 with higher scores indicating more severe steatosis.
This secondary outcome measure is the number of participants that experienced a decrease in steatosis score at 96 weeks compared to baseline, which indicates improvement in steatosis.
|
baseline and 96 weeks
|
|
Number of Participants With Improvement in Lobular Inflammation Score
Tidsramme: baseline and 96 weeks
|
Lobular inflammation is assessed on a scale of 0 to 3 with higher scores indicating more severe lobular inflammation.
This secondary outcome measure is the number of participants that experienced a decrease in lobular inflammation score at 96 weeks compared to baseline, which indicates improvement in lobular inflammation.
|
baseline and 96 weeks
|
|
Number of Participants With Improvement in Ballooning Degradation Score
Tidsramme: baseline and 96 weeks
|
Ballooning is assessed on a scale of 0 to 2 with higher scores indicating more severe ballooning.
This secondary outcome measure is the number of participants that experienced a decrease in ballooning score at 96 weeks compared to baseline, which indicates improvement in ballooning.
|
baseline and 96 weeks
|
|
Change in Body Mass Index
Tidsramme: baseline and 96 weeks
|
baseline and 96 weeks
|
|
|
Change in Serum Vitamin E Levels
Tidsramme: baseline and 96 weeks
|
Change in alpha-Tocopherol
|
baseline and 96 weeks
|
|
Change in Quality of Life (QOL) Scores- Physical Health
Tidsramme: baseline and 96 weeks
|
Change in self-reported QOL physical health Pediatric Quality of Life Inventory (version 4.0) scores were recorded to range from 0 to 100 with increasing scores indicating better quality of life.
|
baseline and 96 weeks
|
|
Change in QOL- Psychosocial Health
Tidsramme: baseline and 96 weeks
|
Change in self-reported QOL physical health Pediatric Quality of Life Inventory (version 4.0) scores were recorded to range from 0 to 100 with increasing scores indicating better quality of life.
|
baseline and 96 weeks
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Generelle publikationer
- Guerrerio AL, Colvin RM, Schwartz AK, Molleston JP, Murray KF, Diehl A, Mohan P, Schwimmer JB, Lavine JE, Torbenson MS, Scheimann AO. Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. Am J Clin Nutr. 2012 Apr;95(4):892-900. doi: 10.3945/ajcn.111.020156. Epub 2012 Feb 15.
- Corey KE, Vuppalanchi R, Vos M, Kohli R, Molleston JP, Wilson L, Unalp-Arida A, Cummings OW, Lavine JE, Chalasani N; Nonalcoholic Steatohepatitis Clinical Research Network. Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2015 Mar;60(3):360-7. doi: 10.1097/MPG.0000000000000584.
- Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Unalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011 Apr 27;305(16):1659-68. doi: 10.1001/jama.2011.520.
- Lavine JE, Schwimmer JB, Molleston JP, Scheimann AO, Murray KF, Abrams SH, Rosenthal P, Sanyal AJ, Robuck PR, Brunt EM, Unalp A, Tonascia J; Nonalcoholic Steatohepatitis Clinical Research Network Research Group. Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp Clin Trials. 2010 Jan;31(1):62-70. doi: 10.1016/j.cct.2009.09.001. Epub 2009 Sep 15.
Hjælpsomme links
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. september 2005
Primær færdiggørelse (Faktiske)
1. september 2009
Studieafslutning (Faktiske)
1. februar 2010
Datoer for studieregistrering
Først indsendt
1. juli 2003
Først indsendt, der opfyldte QC-kriterier
2. juli 2003
Først opslået (Skøn)
3. juli 2003
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
27. september 2012
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
27. august 2012
Sidst verificeret
1. august 2012
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- NASH - PEDIATRICS (IND)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .